



47 million+
people have
Alzheimer's Disease



Almost 10 million
new cases each year



2 in 3 people
with Alzheimer's
Disease are women



**Global cost of Alzheimer's
& Dementia is estimated
to be US \$605bn**




Typical life expectancy after
diagnosis is 4–8 years



Alzheimer's Disease kills
more than breast cancer and
prostate cancer combined

Research for new Alzheimer's Disease treatments


Alzheimer's Disease drug candidates have one of the highest failure rates of any disease area – 99.6% compared with 81% for cancer



**Alzheimer's
drug candidate
failure rate**

105 agents are currently being tested as treatments for Alzheimer's Disease

- 52 – are being investigated in 68 trials in PhII
- 28 – are being investigated in 42 trials in PhIII
- 25 – are being investigated in 29 trials in PhI



- Disease modifying therapies** 70%
- Symptomatic cognitive enhancers** 14%
- Symptomatic agents addressing neuropsychiatric and behavioural changes** 13%
- Undisclosed mechanisms** 2%

ICON is proud to contribute to the investigation of Alzheimer's Disease treatments



Our CNS expertise and patient recruitment capabilities are helping pharma and biotech customers to design better trials and recruit the right patients faster.



Our medical imaging team perform image analysis and modeling for all modalities involved in Alzheimer's trials & has experience with the application of PET, functional and volumetric/anatomical MRI in Alzheimer's trials.



Our innovation team are investigating the use of wearables in Alzheimer's trials to provide objective measures of sleep and activity patterns that are not subject to patient recall bias.